PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
 
PLoS One. 2017; 12(7): e0180988.
Published online 2017 July 13. doi:  10.1371/journal.pone.0180988
PMCID: PMC5509254

Determination of absolute expression profiles using multiplexed miRNA analysis

Yunke Song, Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Software, Validation, Visualization, Writing – original draft, Writing – review & editing,#1 Duncan Kilburn, Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing,#2,* Jee Hoon Song, Data curation, Formal analysis, Investigation, Methodology,3 Yulan Cheng, Data curation, Formal analysis, Investigation, Methodology,3 Christopher T. Saeui, Data curation, Investigation, Methodology,1 Douglas G. Cheung, Data curation, Formal analysis, Investigation, Methodology, Writing – review & editing,4 Carlo M. Croce, Supervision,4 Kevin J. Yarema, Supervision,1 Stephen J. Meltzer, Conceptualization, Funding acquisition, Methodology, Project administration, Resources, Supervision, Writing – original draft, Writing – review & editing,3 Kelvin J. Liu, Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing,2,5 and Tza-Huei Wang, Conceptualization, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Writing – original draft, Writing – review & editing1,5,6,7,*
Sebastien Pfeffer, Editor

Abstract

Accurate measurement of miRNA expression is critical to understanding their role in gene expression as well as their application as disease biomarkers. Correct identification of changes in miRNA expression rests on reliable normalization to account for biological and technological variance between samples. Ligo-miR is a multiplex assay designed to rapidly measure absolute miRNA copy numbers, thus reducing dependence on biological controls. It uses a simple 2-step ligation process to generate length coded products that can be quantified using a variety of DNA sizing methods. We demonstrate Ligo-miR’s ability to quantify miRNA expression down to 20 copies per cell sensitivity, accurately discriminate between closely related miRNA, and reliably measure differential changes as small as 1.2-fold. Then, benchmarking studies were performed to show the high correlation between Ligo-miR, microarray, and TaqMan qRT-PCR. Finally, Ligo-miR was used to determine copy number profiles in a number of breast, esophageal, and pancreatic cell lines and to demonstrate the utility of copy number analysis for providing layered insight into expression profile changes.

Introduction

MicroRNA (miRNA) are short (18–24 nt) non-coding RNA molecules that regulate gene expression. They exert control over a wide variety of cellular processes, ranging from differentiation to growth and senescence [15]. Although over 2000 human miRNA are predicted to exist, individual studies often focus on smaller subsets of 5–50 miRNA that are the presumed critical players in a specific disease or cellular process [3,68]. These miRNA are typically identified by differential expression analysis using highly multiplexed array methods [912] or RNA sequencing [1315]. Validation of identified miRNA is then performed using a higher sensitivity detection platform such as RT-qPCR [1618]. However, screening large numbers of samples across even moderate numbers of miRNA using qRT-PCR quickly becomes cost- and time-prohibitive due to the large numbers of individual reactions that must be performed. Microarray and sequencing can provide large amounts of data but are slow and expensive when only targeted panels are needed.

One additional challenge in miRNA profiling is that quantification bias can lead to both systematic and random variability in expression data. Such variability can manifest across data from different analytical methods, research groups, users, experimental designs, and sample preparation methods. The most common approach to reduce this variability is through normalization. miRNA assays are typically performed using a constant amount of total RNA as input. The resulting expression is then normalized to biological controls [1923], such as small nucleolar RNA (e.g., RNU44, RNU6B) or stably expressed miRNA (e.g., miR-16, let-7a), or to spiking controls (e.g., cel-miR-39) to account for technical variability and variations in baseline transcriptional state. While sources of technical variability are more easily predicted and accounted for using spike-in controls, sources of biological variability are difficult to pinpoint and choosing such internal controls can be quite challenging. Normalization controls can dramatically affect expression profiles and potentially account for much of the reported variability in differential expression profiles, especially for miRNA expressed at low levels with subtle differential changes (<2-fold).

Controls are often chosen empirically by identifying miRNAs that exhibit the lowest variability across a given sample set [22] or those which most closely track the global mean of miRNA expression [23]. Both of these approaches have a central problem: empirically measured parameters—variability, global mean—cannot be measured without proper normalization. Choosing to normalize to a miRNA that exhibits lowest variability is similar to leaving the data un-normalized. Normalization that does not accurately track sources of biological and experimental variability, as may occur based on empirical selection without an understanding of underlying function, can amplify variability and generate artificial trends. RNU44 is commonly, if controversially [20], used as a biological control. Additionally, the global mean expression value has been reported to be a good normalization control [19,21], but this parameter relies on sufficient miRNAs being measured to obtain a reasonable global mean. Exogenous spike in controls have recently been shown to be a reliable normalizer for circulating miRNAs [24,25], particularly when identifying miRNAs with small expression changes [24].

Normalization to reduce methodological errors may also be combined with other approaches, such as adopting the standard practices of the miRQC guidelines [26]. Yet, the most robust approach may be the direct determination of absolute copy number. Unfortunately with existing RT-qPCR, microarray, and sequencing methods, accurate determination of absolute expression (as opposed to relative expression) is tedious and challenging. Digital PCR has been used to determine absolute miRNA expression in human serum [2729]. While digital PCR is sensitive enough to detect even single copies with high repeatability [27], the high cost and complexity make it difficult to screen large numbers of samples across large panels of miRNA.

We have developed a flexible, rapid, and easy-to-use assay called Ligo-miR that can accurately determine miRNA copy number [30]. Ligo-miR uses a multiplex ligation process to generate length-coded, fluorescently-labeled DNA products. The simple length coding enables quantification using a wide variety of DNA sizing methods. Herein, we combine Ligo-miR with polyacrylamide gel electrophoresis (PAGE) detection in a variant called Ligo-miR EZ to perform 26-plex miRNA profiling using only a thermal cycler and PAGE apparatus. This equipment is readily available in nearly all molecular biology labs and makes Ligo-miR EZ ideally suited to repeated profiling of large numbers of samples once a targeted panel has been identified. Minor modifications to the core workflow can be made to custom tailor sensitivity, multiplex capability, and sample throughput based on application and detection methodology. For example, capillary electrophoresis (CE) and single molecule separation [31] may be used instead of PAGE to further enhance multiplex capability and sensitivity.

Ligo-miR EZ's optimized 2-step ligation mechanism enables high multiplex capability and high specificity discrimination of closely-related miRNA species. Specificity studies demonstrate high specificity discrimination of miRNA family members with single nucleotide differences and absolute discrimination of precursor and mature miRNA. A linear amplification, as opposed to exponential amplification, is performed during the 2nd ligation step to enhance sensitivity while minimizing amplification variability and bias for high reproducibility and high differential sensitivity. Analysis of synthetic miRNA, cell lines, and tissue samples show that Ligo-miR EZ is capable of 20 copies per cell sensitivity with linearity across 4.5 orders of magnitude. Analysis of mock expression panels demonstrates that differential sensitivity as low as <1.2 fold is reliably achieved. In direct comparisons to microarray and RT-qPCR, Ligo-miR EZ shows high correlations with r2>0.9. Finally, we use Ligo-miR EZ to determine miRNA copy number in 3 breast cell lines and 5 esophageal cell lines and to quantify the effects of gemcitabine on metastatic pancreatic cancer cells. This system enables direct comparison of copy number expression profiles against relative expression profiles, through which we see that factors such as cell size and baseline transcription can contribute significant variability to expression data.

In addition to reducing bias and variability in miRNA expression profiles, measurement of absolute expression enables the determination of metrics such as accurate rank ordering of expression and comparison of absolute changes in expression. These metrics, alongside the more commonly measured differential changes or proportional quantification, open up an array of new tools for comparing expression profiles across patients, samples, and disease model systems.

Materials and methods

Cell line samples

Primary, normal, non-immortalized esophageal epithelial cells (HEEPIC), along with esophageal cancer cell lines (SKGT4 and OE33), were purchased from ScienCell Research Laboratories (Carlsbad, California, USA) and Sigma Chemical (St Louis, Missouri, USA), respectively. The Barrett’s esophageal cell lines (CHTRT and QHTRT) were generous gifts of Dr. Peter Rabinovitch, Fred Hutchinson Cancer Center.

Breast cell lines (MCF-7, MCF-10A, and MDA-MB-231) and the metastatic pancreatic cancer cell line were purchased from ATCC (Manassas, VA).

Details of cell culturing protocols can be found in S1 File.

Total RNA/Small RNA fraction preparation

Total RNA was isolated from the esophageal cell lines using RNeasy kits (Qiagen, Valencia, CA), combined with RNase-free DNase (Qiagen, #79254), with TRIzol reagent (Life Technologies, Carlsbad, CA) used instead of the QIAzol. For the RT-qPCR and microarray experiments, this total RNA was used directly. For Ligo-miR EZ analysis, the small RNA fraction was isolated from this total RNA using both miRNeasy (Qiagen, Valencia, CA) and mirPremier (Sigma-Aldrich, St. Louis, MO) kits. The small RNA fraction was isolated directly from the breast cell lines using miRNeasy and mirPremier kits. Total RNA was isolated from the metastatic pancreatic cancer cells using miRNeasy kits. Pancreatic total RNA was purchased from Ambion (FirstChoice Human Pancreas RNA, catalog # AM7954).

miRNA and probe synthesis

All RNA and DNA oligonucleotides (S1 File, Tables S2-S4) were synthesized by Integrated DNA Technologies (Coralville, IA) and re-suspended to give 100 μM stocks. All synthetic miRNA were further diluted to 1 μM concentration in TE buffer (10 mM Tris-HCl, pH = 8.0, 0.1 mM EDTA) and stored at -80°C. These aliquots were used to prepare lower concentration stocks and discarded after single use to guard against degradation. Further details on miRNA and probe handling protocols can be found in S1 File.

Ligo-miR EZ assay

In the capture ligation step, the RNA sample was added to a mastermix containing the adenylated adapter, T4 RNA ligase, and buffer and incubated at 25°C for 1 hour. Then in the coding ligation, a 2nd mastermix containing the common probe, 26-plex discrimination probes, 9°N DNA ligase, and buffer was added to the 1st step products and thermal cycled for 50 cycles. Finally, the 2nd step reaction mixture was analyzed using 15% denaturing urea PAGE gel and scanned using a GE Typhoon 9410 multi-mode imager. The fluorescent gel images were analyzed using either HandyBand software (Circulomics Inc) or using a combination [32] of ImageQuant (GE Healthcare) and OriginPro (OriginLab). Specific details can be found in S1 File.

RT-qPCR and microarray assays

Single tube Applied Biosystems TaqMan microRNA Assays, Applied Biosystems TaqMan MicroRNA Reverse Transcription Kit, and Bio-Rad iQ Supermix were used for the RT-qPCR assays. Assays were run on an Applied Biosystems 7900HT Real-Time PCR System. 5 ng of total RNA was used as input for each RT reaction and performed according to the manufacturer’s protocol.

Microarray analysis was performed by the JHMI Deep Sequencing and Microarray Core using Agilent Human miRNA Microarray Kit Release 19.0, 8x60K (G4872A, Agilent Technologies, Santa Clara, CA) following manufacturer’s protocols.

Full details of RT-qPCR and Microarray protocols can be found in S1 File.

Results and discussion

Assay principle

Ligo-miR EZ uses a 2-step ligation mechanism schematically illustrated in Fig 1. In the capture ligation step, a universal adapter is ligated to the 3' end of all sample miRNA to form templates. Reaction conditions and adapter design have been optimized previously [32] to ensure high efficiency (86%) and low capture bias (10% CV). Then in the coding ligation step, up to 26 miRNA specific discrimination probes (DPs) and an Alexa647-labeled common probe (CP) are hybridized to the miRNA templates from the first step and ligated together to form a single stranded DNA product. Each DP contains a recognition sequence at the 5' end that is complementary to the miRNA being detected and a length tag at the 3' end to yield a specific length product for each miRNA species. The CP sequence is complementary to the adapter probe and not miRNA specific. Thermal cycling is used to perform a 50X linear amplification by repeatedly generating Ligo-miR EZ products from each miRNA template. The Ligo-miR EZ products are then analyzed by polyacrylamide gel electrophoresis (PAGE). Circulomics HandyBand software is used to analyze the resultant gel image and determine miRNA expression based on band position and intensity.

Fig 1
Schematic illustration of the Ligo-miR EZ multiplex miRNA assay.

Sensitivity and bias

Serial dilutions of synthetic miRNA, pancreatic small RNA, and pancreatic total RNA were used to determine the assay sensitivity, dynamic range, linearity, and bias. Fig 2a shows an image of the gel resulting from a 26-plex Ligo-miR EZ analysis performed on a serial dilution of synthetic miRNA. The assay shows a linear response between miRNA input and band fluorescence over several orders of magnitude and a sensitivity as low as 0.5 attomoles when scanned using a high sensitivity imager such as GE's Typhoon 9410 (Fig 2b and S1 File, Table S1). At standard input levels, this translates to approximately 20–500,000 copies per cell, overlapping expected cellular expression levels. When rigorously performed, gel quantification and image analysis can be highly sensitive and repeatable, capable of measurement CVs <10% and sensitivity <5 attomoles of fluorophore [32].

Fig 2
Ligo-miR EZ sensitivity and reproducibility data.

The response from a serial dilution of small RNA isolated from pancreatic total RNA is shown in Fig 2d. However, below 75 ng of total RNA equivalent input, lowly expressed miRNA begin dropping below the sensitivity threshold, reducing the number of detectable bands. When total RNA is used as sample input as opposed to small RNA, inhibition can be seen at inputs >100 ng (Fig 2e). Rising levels of background RNA inhibit the coding ligation efficiency, offsetting signal increase and leading to a plateau in response. At each given input level, the degree of inhibition varies with miRNA species, but is repeatable and can be effectively normalized using reference curves obtained with MS2 phage RNA (S1 File, Fig S1). It is important to note that this inhibition does not reduce individual miRNA response curve linearity or dynamic range but can reduce overall signal intensity impacting sensitivity.

Amplification bias has been minimized by optimizing reaction conditions to suppress ligation bias [32,33] and by optimizing probe design via thermodynamic analysis. Amplification bias can be determined by analyzing the spread in the fluorescent intensity across miRNA. Across the 56 miRNA tested in total, no systematic trends were observed with factors such as probe Tm, miRNA GC content, or miRNA 3’ base (S1 File, Fig S2). However, predictable differences were seen due to tag length (S1 File, Fig S3). After optimization, the raw band fluorescence for given miRNA input, as seen in Fig 2b and S1 File, Fig S9, varies less than 10X max-min across a typical Ligo-miR EZ panel.

Reproducibility and robustness

Assay reproducibility was first examined by comparing the raw band intensities for replicate experiments at varying cell inputs. Ligo-miR EZ was highly reproducible at both high (r2 = 0.98) and low (r2 = 0.93) input levels (Fig 2f). For a long—term test of repeatability, we created a synthetic panel containing 1500 attomoles of each of 26 miRNAs. 28 repeats of this experiment spanning a period of 3 months generated an inter-day mean CV of 22% for the raw band fluorescence (S1 File, Fig S4) and 13% when normalized to miR-16-5p. Fig 2g shows the distribution of all measurements when normalized against the mean for each miRNA. For a perfect assay this distribution would be a delta function at 0 –i.e. no deviation from the mean. The distribution of the raw deviations is centered around 0, but there is a prominent side peak centered at -0.2 due to drift in scanner performance. When the band intensities were normalized, the distribution became tight and symmetric. A separate analysis determined that the intraday mean CVs of raw and normalized band intensities from 1500 attomoles were 7.9% and 5.8%, respectively (S1 File, Fig S5).

When Ligo-miR EZ was used to compare MCF-7 total RNA and small RNA inputs (S1 File, Fig S6), high correlation (r2 = 0.96) was seen. However, higher signal intensities were seen with small RNA than total RNA. High correlation was also seen when comparing small RNA isolated with either Qiagen miRNeasy or Sigma mirPremier kits (S1 File, Fig S7). Interestingly, two of the outlier data points were due to RNU44, which at 61 nts is considerably longer than miRNA. We hypothesize that this outlier may arise due to length dependent biases from different small RNA isolation chemistries employed by the two kits. This discrepancy underscores the inherent risk in using normalization controls that differ in length or structure from the miRNA being measured [22,23]. In aggregate, these data demonstrate that Ligo-miR EZ is very reproducible and robust across common sample types and sample preparation methods.

Specificity

High assay specificity is particularly important in miRNA profiling as hundreds of different miRNA can be present in any single sample. This diversity often includes families of miRNA with closely-related sequences, isomiRs with minor 5' and 3' modifications, and transcripts with mature, precursor, and primary forms. Synthetic miRNA and probe sets were designed to test assay specificity. Across unrelated miRNA, Ligo-miR EZ exhibited perfect discrimination with no detectable cross-talk (Fig 3a). Cross-talk was only observed between the miRNAs in lanes 11 and 18, which correspond to miR-106a-5p and miR-17-5p. These miRNA both come from the miR-17 precursor family and differ by only a single nucleotide at the 5’ end (S1 File, Table S2).

Fig 3
Ligo-miR EZ specificity data.

To test closely-related miRNA, we designed a probe set to profile 8 members of the let-7 family, 7 of which differ by only 1 or 2 nts (S1 File, Table S3). Limited cross-talk was seen in 12 of 56 off miRNA combinations (Fig 3b). Cross-talk greater than 5% was only seen in 5 probe:miRNA combinations: let-7f:let-7a, let-7c:let-7b, let-7a:let-7c, let-7a:let-7d, and let-7a:let-7e. Ligo-miR EZ is expected to be more sensitive to probe:miRNA mismatches near the ligation site due to the combination of thermodynamic mismatch discrimination and ligase mismatch discrimination. Such behavior is common to ligation assays [3436] as mismatches far from the ligation site no longer sit within the ligase's active site [35], leaving thermodynamic discrimination as the remaining force. Thus, it was not unexpected that the greatest degree of cross-talk was seen between probe:miRNA pairs where the mismatch occurred far from the ligation site such as let-7a:let-7e (14 bases), let-7a:let-7d (7 bases), let-7c:let-7b (6 bases), and let-7f:let-7a (11 bases). Similar overall levels of cross-talk are seen in other hybridization assays [26], though some of these studies relied on earlier miRBase annotations that contained let-7 miRNA of differing lengths [16].

Across precursor and mature miRNA, Ligo-miR EZ exhibited absolute discrimination. Precursor let-7a (S1 File, Table S4) and mature let-7a miRNA were mixed in different ratios and analyzed using a single-plex let-7a discrimination probe. Even in a high background of precursor molecules, no cross-talk was seen (Fig 3c). As seen above, the 2-step ligation mechanism renders the assay extremely sensitive to variations at the miRNA 3' end. Modifications close to this end will be discriminated with high specificity while insertions or deletions will be discriminated with absolute specificity.

Differential sensitivity

Many applications of miRNA profiling involve measuring differential expression to identify up- or down-regulated miRNAs. To quantify differential expression sensitivity, we made 4 samples (S1, S2, S3 and S4) containing 26 synthetic miRNA (4 internal controls, 20 miRNAs, 2 snRNAs) in a manner analogous to the miRQC study [26]. Base samples S1 and S2 were titrated to generate samples S3 = 0.25*S1 + 0.75*S2 and S4 = 0.75*S1 + 0.25*S2. This enabled differential sensitivity testing at low (10 attomoles), medium (100 attomoles), and high (1000 attomoles) expression levels with maximum fold-changes of 3, 3, and 2, respectively (S1 File, Fig S8). The smallest ratio between two bands is the 1.14-fold difference between S3 and S2 at the 1000 attomoles level.

Ligo-miR EZ was then performed on each of the 4 samples in duplicate. A gel image from one replicate is shown in Fig 4a. We found that 19 of the 22 miRNA, or 90.5%, displayed the correct titration response (S1 < S4 < S3 < S2). For example, the band intensities for miR-15a-5p increase as expected. This measure of differential sensitivity is particularly stringent because it requires correctly resolving differences as small as 1.14-fold and no larger than 3-fold for every miRNA tested. Fig 4b and 4c plots the measured differential ratio against the expected ratio. The data are tightly packed around the correct differential response, y = x. The measured differential ratio differs from the expected ratio by an average of 9.7%, 13.4%, and 44% for the 1000, 100, and 10 attomole inputs, respectively. The 10 attomole level is dominated by two outlier measurements. Removing the 6 differential pairs resulting from these two measurements reduces this difference to 24%. Given Ligo-miR's high reproducibility (5.8% intraday CV for raw fluorescence from 1500 attomoles input miRNA), measured 1.14-fold changes have a p-value of 0.069 (Independent two-sample t-test, one tailed probability). Thus, measured changes of this magnitude should be correctly resolved with 93% certainty using duplicate measurements. Larger changes of 1.5-fold should be resolved with 99% certainty. In this experiment, 40 pairs of measurements involve difficult to resolve differences of 1.5-fold or less; of these, 98% are resolved correctly. Compared to existing methods, Ligo-miR is therefore functionally capable of improving differential sensitivity when investigating subtle changes caused by either small expression changes in large numbers of cells or large expression changes in small numbers of driver cells.

Fig 4
Differential sensitivity and benchmarking of Ligo-miR EZ.

Benchmarking against RT-qPCR and microarray

To benchmark Ligo-miR EZ performance, we profiled 5 esophageal cell lines (HEEPIC, CHTRT, QHTRT, SKGT4, and OE33) and compared against Applied Biosystems TaqMan RT-qPCR and Agilent microarray. RNA was pooled for each cell line to eliminate variation from sample preparation and cell culture. Ligo-miR EZ was performed using a 26-plex probe set (Panel A), resulting in 5 total reactions. TaqMan was performed across 21 miRNA using triplicate RT and duplicate qPCR steps, resulting in 630 total qPCR reactions (S1 File, Table S5). Of these, 77 outliers were identified due to anomalous amplification curves, and 18 reactions did not result in any amplification; these 95 traces were omitted when calculating the mean Cts used in differential analysis (S1 File, Tables S6). The average standard deviation across all miRNA (excluding null results but including outliers) is 0.71 Cts, corresponding to an expression difference of 63%. We further measured miR-106b-5p for all cells on three separate days to quantify day-to-day technical variation (S1 File, Table S7). The average standard deviation of the raw Cts is 0.58, corresponding to a variation in miRNA expression of 48%, which is significantly higher than the equivalent measure from Ligo-miR EZ, 22%. Microarray was performed according to the manufacturer’s protocol using a single Agilent slide with 8 arrays, each containing probes for 2006 miRNA. Expression values are provided in S1 File, Table S8.

Differential expression was calculated by dividing the miRNA expression level in each cell line against OE33. The differential expression obtained using RT-qPCR is plotted against that from Ligo-miR EZ in Fig 4d and shows that the two methods agree well with a strong linear fit (gradient = 0.91 ± 0.05, r2 = 0.93). An equivalent comparison between microarray and Ligo-miR EZ is shown in Fig 4e and demonstrates good correlation (gradient = 0.84 ± 0.05, r2 = 0.92), although the lower gradient may suggest a systematic difference in expression response between the two methods. Finally, Fig 4f compares the differential expression profiles from RT-qPCR against microarray (gradient = 1.00 ± 0.04, r2 = 0.95) and also shows good agreement. Thus, all the measurement platforms obtain similar expression profiles, and Ligo-miR performs equally as well as the two established technologies. Equivalent correlation values between a variety of different sequencing and microarray platforms and RT-qPCR were previously measured to be between 0.68 and 0.92 [37]. The agreement between miRNA expression measured by Ligo-miR EZ and RT-qPCR is therefore among the highest found between the methods.

Absolute copy number determination

A major strength of Ligo-miR EZ is the ease with which absolute miRNA copy numbers per cell (or copies per ng of total RNA) can be measured. Absolute copy number is determined by spiking technical controls into the cell pellet and into the various reaction master mixes to account for differences in technical efficiency (Fig 5a) and then comparing the signal against a 4 point standard curve (S1 File, Fig S9). These steps can be integrated into the analysis as a matter of routine with negligible additional effort. To demonstrate the strength and feasibility of this approach, we used Ligo-miR EZ Panels A, B, C, and D to determine miRNA copy numbers in 3 breast cell lines (MCF-10A, MDA-MB-231, and MCF-7) and 5 esophageal cell lines (HEEPIC, CHTRT, QHTRT, SKGT4, and OE33). Two separate experimental designs were employed. For the breast cell lines, a constant input of 33,333 cells was used per reaction. For the esophageal cell lines a constant input of 500 ng of total RNA was used for each reaction, akin to standard differential expression analysis, and 15 pg of total RNA per cell was assumed for all calculations.

Fig 5
Absolute miRNA copy number using Ligo-miR EZ.

The absolute copy numbers per cell are shown in Fig 5b. The average measurement CV (S1 File, Fig S10) across all miRNA was 30%, and, as expected, lowly expressed miRNA (<1000 copies per cell) had higher variance than highly expressed miRNA (>1000 copies). These copy number CVs are higher than the previous raw fluorescence CVs as they also include variance from the spike-in and standard curve measurements. Given a mean intra-day CV of 12% for the raw fluorescence (15–1500 attomoles), we expect 99% of absolute copy numbers to be within 50% of their true value. Lower expressed miRNAs with higher intraday CVs will have correspondingly less accurate absolute number determination. The measured copy numbers ranged from 15–147,056 copies per cell and generally fell within the expected range based on previous studies [3840]. Oncogenic miRNA such as miR-21-5p [7,8,4143] are highly expressed in the cancer cell lines (MCF-7, MDA-MB-231, OE33, and SKGT4) and lowly expressed in the normal cell lines (HEEPIC and MCF10A). Conversely, the tumor suppressor miR-205-5p [4146] is significantly overexpressed in the normal cell lines compared with the cancer cell lines. However, we do not see reduced expression in the cancer cell lines for some other commonly reported tumor suppressors such as let-7a-5p [4143,47], miR-15a-5p, and miR-16-5p. This apparent discrepancy may not be significant, however, since most of the results for miR-15a-5p and miR-16-5p come from leukemia studies [4850] with limited work relating to solid tumors [5156]. Total miRNA expression and the number of detected miRNA also appear to increase when comparing non-cancer and cancer cells. We note that the commonly used biological controls RNU6B and RNU44 varied widely between the samples, regardless of whether the input was constant cell number or constant total RNA, highlighting concerns from previous studies [20] over the suitability of these controls. As this miRNA expression data comes from cell lines, the trends will likely differ from that found in clinical samples.

Differential expression analysis

Analyzing differential expression using absolute copy numbers is a powerful alternative to biological normalization that can provide layered insight into miRNA expression profiles. This method reduces bias from the assay and reduces dependency on biological controls. To explore this advantage, we determined absolute expression profiles (S1 File, Table S9) using Ligo-miR EZ Panel E on a metastatic pancreatic cancer cell line treated with 0 (G0), 1 (G1), or 10 (G10) μM of the chemotherapy drug gemcitabine. Measurements of RNA isolation yield showed that gemcitabine treatment significantly reduces the total RNA per cell and corroborates the observation that cell size shrinks with increased dosage. Ligo-miR EZ analysis was performed on each of the three samples in quadruplicate using two experimental designs, a constant total RNA input of 75 ng or a constant cell input of 10,000 cells. Overall, we can see that total miRNA and RNU44 expression levels appear to be correlated (S1 File, Fig S11) and decrease with increasing gemcitabine dosage.

Looking in greater detail, we see that the fluorescent intensities from the constant RNA input and constant cell input cases are linearly related with a slope that is equal to the difference in input amount (Fig 6a). Biological controls such as RNU44 are often used to adjust for variances in baseline transcription and input amounts [20]. Fig 6b shows that for this data set RNU44 is effective at normalizing RNA input; after RNU44 normalization, the constant cell and constant RNA input data sets collapse onto one another, eliminating differences due to experimental design. Alternatively, analysis of absolute copy number can also eliminate such differences resulting from experimental design (Fig 6c). This type of normalization is particularly important since treatments such as gemcitabine can dramatically alter the transcriptional state of the cell and generate opposing expression trends depending on experimental design.

Fig 6
Different normalization approaches give different differential expression profiles.

Fig 6d shows the effect of various normalization strategies on the interpretation of miR-17-5p expression. With constant RNA input, the expression of miR-17 appears to increase with gemcitabine treatment. However, with constant cell input, miR-17 expression appears to decrease with gemcitabine treatment. Normalization of the fluorescence to RNU44 brings the constant RNA and constant cell data into alignment, with both showing a decrease in miR-17 expression with gemicitabine treatment. The RNU44 normalized data matches the copies per cell data and fractional expression data (miR-17 / total miR expression), with both showing that miR-17 expression decreases. These normalization and experimental design issues may partially explain disagreement, even in seminal work, about whether known oncogenic miRNA such as miR-17 are up- or down- regulated in tumors [7,57]. Our data show that miR-17 decreases with increasing gemcitabine dosage in terms of copies per cell, as a proportion of total miRNA expression, and with respect to RNU44. As a nucleotide analog, it is not unexpected that gemictabine would lead to reduced expression of miR-17, a known regulator of the cell cycle [58] and apoptosis [59].

Next, we calculated differential expression ratios for both the constant RNA and constant cell data sets by dividing the G1 and G10 expression levels by the G0 expression level. Fig 6e shows that differential ratios obtained using either the RNU44 normalized fluorescence or copies per cell data give nearly identical results. The majority of miRNA are down-regulated by gemcitabine treatment with small discrepancies seen at low differential ratios due to measurement and normalization variability. This type of differential analysis typically identifies miRNA of interest by finding those that display the highest differential ratios. In practice, the miRNA with the highest differential ratios are often those that go from undetectable to lowly expressed. As the overall expression values of these miRNA are still small, it is debatable whether these miRNA have any biological significance or effect within the cell.

Copy number profiles provide an alternative metric. Fractional expression can be determined by comparing the levels of each miRNA against the total miRNA expression within the cell. Differential comparison can be then made to examine both the ratiometric change and the absolute change. Hence, a miRNA with fractional expression that changes from 0.1% to 1% will have a smaller absolute change than a miRNA that changes from 1% to 10% despite having the same differential ratio. Fig 6f plots the differential ratio calculated using RNU44 normalized fluorescence against the absolute difference calculated from fractional expression. While the direction of change is largely preserved, the magnitude changes greatly. Some miRNA with high differential ratios have low absolute differences (e.g., miR-205-5p). Yet others with low differential ratios have high absolute differences (e.g., miR-21-5p). The greater the number of miRNA analyzed, the more accurate the fractional expression will be as the impact of individual miRNA on overall miRNA levels is reduced.

Examining miRNA in terms of absolute changes can provide layered insight into miRNA function within cells and potentially aid in identification of new biomarkers. The differences between normalizing miRNA expression to cell number, total miRNA expression, and biological controls highlight a significant challenge for miRNA measurement with biological consequences. What is more important for a miRNA's function: its expression per cell, its expression per total RNA, its expression per biological control, or its expression as a proportion of all miRNA? As we have shown, differential expressions with these normalization methods can result in misidentification of increased/decreased miRNA expression in diseased cells. Additionally, the biological relevance of ratiometric increases in expression or absolute increases in miRNA copy number per cell must be given consideration. Ligo-miR EZ provides scientists a routine method for multiplexed analysis of miRNA copy number that does not involve significant extra work, cost, or proprietary instruments. However, the convenience of fluorescent PAGE detection limits Ligo-miR EZ to 26-plex profiling and 20 copies per cell sensitivity. In future iterations, the core ligation process can be easily expanded to higher multiplexed levels, modified to further enhance sensitivity, combined with other detection systems for higher throughput, and used as a platform for broad applications in miRNA profiling.

Supporting information

S1 File

Supplementary methods.

(DOCX)

Acknowledgments

Samples quality assessment and microarray analysis were conducted at The Sidney Kimmel Cancer Center Microarray Core Facility at Johns Hopkins University. Dr. Meltzer is an American Cancer Society Clinical Research Professor and the Harry and Betty Myerberg Professor of Gastroenterology. DCG received support from the OSU/HHMI Med into Grad Scholars Program.

Funding Statement

This work was supported by the National Institute of Health [grant numbers 1R43GM103360, 2R44GM103360, F31CA192767, 5R21CA191715,T32-GM086252 to DGC, P30 CA006973, CA190040, CA211457, R21CA173390, R21CA186809]; Johns Hopkins University [JHU Synergy Award]; OSU/HHMI Med into Grad Scholars Program.

Data Availability

Data Availability

All relevant data are within the paper and its Supporting Information files. We have uploaded the raw microarray files to ArrayExpress. The Accession number is E-MTAB-5575.

References

1. Iorio M V, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med. 2012;4: 143–59. doi: 10.1002/emmm.201100209 [PMC free article] [PubMed]
2. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6: 857–66. doi: 10.1038/nrc1997 [PubMed]
3. Garzon R, Calin GA, Croce CM. MicroRNAs in Cancer. Annu Rev Med. 2009;60: 167–79. doi: 10.1146/annurev.med.59.053006.104707 [PubMed]
4. Pereira DM, Rodrigues PM, Borralho PM, Rodrigues CMP. Delivering the promise of miRNA cancer therapeutics. Drug Discov Today. 2013;18: 282–9. doi: 10.1016/j.drudis.2012.10.002 [PubMed]
5. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010;9: 775–89. doi: 10.1038/nrd3179 [PMC free article] [PubMed]
6. Keller A, Leidinger P, Bauer A, Elsharawy A, Haas J, Backes C, et al. Toward the blood-borne miRNome of human diseases. Nat Methods. 2011;8: 841–3. doi: 10.1038/nmeth.1682 [PubMed]
7. Volinia S, Calin GA, Liu C-G, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006;103: 2257–2261. doi: 10.1073/pnas.0510565103 [PubMed]
8. Iorio M V, Ferracin M, Liu C-G, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65: 7065–70. doi: 10.1158/0008-5472.CAN-05-1783 [PubMed]
9. Worley LA, Long MD, Onken MD, Harbour JW. Micro-RNAs associated with metastasis in uveal melanoma identified by multiplexed microarray profiling. Melanoma Res. 2008;18: 184–190. doi: 10.1097/CMR.0b013e3282feeac6 [PubMed]
10. Sorbara L, Kishawi I, Pinsky P, Meltzer S, Franklin W, Bemis L, et al. Abstract #5383: MicroRNA microarrays for biomarker discovery: Joint EDRN-Agilent project. Cancer Res. 2014;69.
11. Sato F, Tsuchiya S, Terasawa K, Tsujimoto G. Intra-Platform Repeatability and Inter-Platform Comparability of MicroRNA Microarray Technology. Selvarajoo K, editor. PLoS One. Public Library of Science; 2009;4: e5540 doi: 10.1371/journal.pone.0005540 [PMC free article] [PubMed]
12. Wyman SK, Knouf EC, Parkin RK, Fritz BR, Lin DW, Dennis LM, et al. Post-transcriptional generation of miRNA variants by multiple nucleotidyl transferases contributes to miRNA transcriptome complexity. Genome Res. Cold Spring Harbor Laboratory Press; 2011;21: 1450–1461. doi: 10.1101/gr.118059.110 [PubMed]
13. van Nieuwerburgh F, Soetaert S, Podshivalova K, Ay-Lin Wang E, Schaffer L, Deforce D, et al. Quantitative bias in illumina TruSeq and a novel post amplification barcoding strategy for multiplexed DNA and small RNA deep sequencing. Lightowlers B, editor. PLoS One. Public Library of Science; 2011;6: e26969 doi: 10.1371/journal.pone.0026969 [PMC free article] [PubMed]
14. Burgos KL, Javaherian A, Bomprezzi R, Ghaffari L, Rhodes S, Courtright A, et al. Identification of extracellular miRNA in human cerebrospinal fluid by next-generation sequencing. RNA. Cold Spring Harbor Laboratory Press; 2013;19: 712–722. doi: 10.1261/rna.036863.112 [PubMed]
15. Jenjaroenpun P, Kremenska Y, Nair VM, Kremenskoy M, Joseph B, Kurochkin I V. Characterization of RNA in exosomes secreted by human breast cancer cell lines using next-generation sequencing. PeerJ. PeerJ Inc.; 2013;1: e201 doi: 10.7717/peerj.201 [PMC free article] [PubMed]
16. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. Oxford University Press; 2005;33: e179 doi: 10.1093/nar/gni178 [PMC free article] [PubMed]
17. Wan G, Lim QE, Too H-P. High-performance quantification of mature microRNAs by real-time RT-PCR using deoxyuridine-incorporated oligonucleotides and hemi-nested primers. RNA. 2010;16: 1436–1445. doi: 10.1261/rna.2001610 [PubMed]
18. Yao Y, Suo A-L, Li Z-F, Liu L-Y, Tian T, Ni L, et al. MicroRNA profiling of human gastric cancer. Mol Med Rep. 2009;2: 963–970. doi: 10.3892/mmr_00000199 [PubMed]
19. Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F, et al. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol. 2009/06/18. 2009;10: R64 doi: 10.1186/gb-2009-10-6-r64 [PMC free article] [PubMed]
20. Gee HE, Buffa FM, Camps C, Ramachandran A, Leek R, Taylor M, et al. The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. Br J Cancer. 2011;104: 1168–1177. doi: 10.1038/sj.bjc.6606076 [PMC free article] [PubMed]
21. D’Haene B, Mestdagh P, Hellemans J, Vandesompele J. miRNA expression profiling: from reference genes to global mean normalization. Methods Mol Biol. 2011/12/07. 2012;822: 261–272. doi: 10.1007/978-1-61779-427-8_18 [PubMed]
22. Han HS, Jo YN, Lee JY, Choi SY, Jeong Y, Yun J, et al. Identification of suitable reference genes for the relative quantification of microRNAs in pleural effusion. Oncol Lett. 2014;8: 1889–1895. doi: 10.3892/ol.2014.2404 [PMC free article] [PubMed]
23. Ayers D, Mestdagh P, Van Maerken T, Vandesompele J. Identification of miRNAs contributing to neuroblastoma chemoresistance. Comput Struct Biotechnol J. 2015/05/15. 2015;13: 307–319. doi: 10.1016/j.csbj.2015.04.003 [PMC free article] [PubMed]
24. Roberts TC, Coenen-Stass AML, Wood MJA. Assessment of RT-qPCR normalization strategies for accurate quantification of extracellular microRNAs in murine Serum. Mukhopadhyay P, editor. PLoS One. Public Library of Science; 2014;9: e89237 doi: 10.1371/journal.pone.0089237 [PMC free article] [PubMed]
25. Vigneron N, Meryet-Figuière M, Guttin A, Issartel JP, Lambert B, Briand M, et al. Towards a new standardized method for circulating miRNAs profiling in clinical studies: Interest of the exogenous normalization to improve miRNA signature accuracy. Molecular Oncology. 2016: 981–992. doi: 10.1016/j.molonc.2016.03.005 [PMC free article] [PubMed]
26. Mestdagh P, Hartmann N, Baeriswyl L, Andreasen D, Bernard N, Chen C, et al. Evaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study. Nat Methods. 2014/06/30. 2014;11: 809–815. doi: 10.1038/nmeth.3014 [PubMed]
27. Hindson CM, Chevillet JR, Briggs HA, Gallichotte EN, Ruf IK, Hindson BJ, et al. Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat Methods. Nature Research; 2013;10: 1003–1005. doi: 10.1038/nmeth.2633 [PMC free article] [PubMed]
28. Ma J, Li N, Guarnera M, Jiang F. Quantification of Plasma miRNAs by Digital PCR for Cancer Diagnosis. Biomark Insights. Libertas Academica; 2013;8: 127–136. doi: 10.4137/BMI.S13154 [PMC free article] [PubMed]
29. Miotto E, Saccenti E, Lupini L, Callegari E, Negrini M, Ferracin M. Quantification of circulating miRNAs by droplet digital PCR: comparison of EvaGreen- and TaqMan-based chemistries. Cancer Epidemiol Biomarkers Prev. 2014;23: 2638–2642. doi: 10.1158/1055-9965.EPI-14-0503 [PubMed]
30. Kilburn D, Song Y, Wang T-H, Liu KJ. A Multiplex Ligation Assay for miRNA Copy Number Profiling. Methods Mol Biol. 2017;1509: 185–193. doi: 10.1007/978-1-4939-6524-3_17 [PubMed]
31. Liu KJ, Rane TD, Zhang Y, Wang T-H. Single-molecule analysis enables free solution hydrodynamic separation using yoctomole levels of DNA. J Am Chem Soc. 2011;133: 6898–6901. doi: 10.1021/ja200279y [PMC free article] [PubMed]
32. Song Y, Liu KJ, Wang TH. Elimination of ligation dependent artifacts in T4 RNA ligase to achieve high efficiency and low bias microRNA capture. PLoS One. Public Library of Science; 2014;9. [PMC free article] [PubMed]
33. Song Y, Liu KJ, Wang T. Efficient synthesis of stably adenylated DNA and RNA adapters for microRNA capture using T4 RNA ligase 1. Nat Publ Gr. Nature Publishing Group; 2015;5: 1–8. doi: 10.1038/srep15620 [PMC free article] [PubMed]
34. Barany F. Genetic disease detection and DNA amplification using cloned thermostable ligase. Proc Natl Acad Sci U S A. 1991;88: 189–93. doi: 10.1073/pnas.88.1.189 [PubMed]
35. Lohman GJS, Bauer RJ, Nichols NM, Mazzola L, Bybee J, Rivizzigno D, et al. A high-throughput assay for the comprehensive profiling of DNA ligase fidelity. Nucleic Acids Res. 2016;44: e14 doi: 10.1093/nar/gkv898 [PMC free article] [PubMed]
36. Showalter AK, Lamarche BJ, Bakhtina M, Su MI, Tang KH, Tsai MD. Mechanistic comparison of high-fidelity and error-prone DNA polymerases and ligases involved in DNA repair. Chemical Reviews. 2006. pp. 340–360. doi: 10.1021/cr040487k [PubMed]
37. Git A, Dvinge H, Salmon-Divon M, Osborne M, Kutter C, Hadfield J, et al. Systematic comparison of microarray profiling, real-time PCR, and next-generation sequencing technologies for measuring differential microRNA expression. RNA. Cold Spring Harbor Laboratory Press; 2010;16: 991–1006. doi: 10.1261/rna.1947110 [PubMed]
38. Liang Y, Ridzon D, Wong L, Chen C. Characterization of microRNA expression profiles in normal human tissues. BMC Genomics. BioMed Central; 2007. p. 166 doi: 10.1186/1471-2164-8-166 [PMC free article] [PubMed]
39. Lu J, Tsourkas A. Imaging individual microRNAs in single mammalian cells in situ. Nucleic Acids Res. Oxford University Press; 2009;37: e100 doi: 10.1093/nar/gkp482 [PMC free article] [PubMed]
40. Veigaard C, Kjeldsen E. Exploring the genome-wide relation between copy number status and microRNA expression. Genomics. 2014;104: 271–278. doi: 10.1016/j.ygeno.2014.08.002 [PubMed]
41. Kestens C, Siersema PD, Van Baal JWPM. Current understanding of the functional roles of aberrantly expressed microRNAs in esophageal cancer. World Journal of Gastroenterology. 2016. pp. 1–7. doi: 10.3748/wjg.v22.i1.1 [PMC free article] [PubMed]
42. Amin M, Lam AK yin. Current perspectives of mi-RNA in oesophageal adenocarcinoma: Roles in predicting carcinogenesis, progression and values in clinical management. Experimental and Molecular Pathology. 2015. pp. 411–418. doi: 10.1016/j.yexmp.2015.03.002 [PubMed]
43. Sempere LF, Christensen M, Silahtaroglu A, Bak M, Heath C V., Schwartz G, et al. Altered microRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res. 2007;67: 11612–11620. doi: 10.1158/0008-5472.CAN-07-5019 [PubMed]
44. Wu H, Mo Y-Y. Targeting miR-205 in breast cancer. Expert Opin Ther Targets. 2009;13: 1439–48. doi: 10.1517/14728220903338777 [PubMed]
45. Piovan C, Palmieri D, Di Leva G, Braccioli L, Casalini P, Nuovo G, et al. Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer. Mol Oncol. 2012;6: 458–472. doi: 10.1016/j.molonc.2012.03.003 [PMC free article] [PubMed]
46. Wu H, Zhu S, Mo Y-Y. Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res. 2009;19: 439–448. doi: 10.1038/cr.2009.18 [PMC free article] [PubMed]
47. Yang H, Gu J, Wang KK, Zhang W, Xing J, Chen Z, et al. MicroRNA expression signatures in Barrett’s esophagus and esophageal adenocarcinoma. Clin Cancer Res. 2009;15: 5744–52. doi: 10.1158/1078-0432.CCR-09-0385 [PMC free article] [PubMed]
48. Calin GA, Cimmino A, Fabbri M, Ferracin M, Wojcik SE, Shimizu M, et al. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci U S A. 2008;105: 5166–71. doi: 10.1073/pnas.0800121105 [PubMed]
49. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. National Academy of Sciences; 2002;99: 15524–15529. doi: 10.1073/pnas.242606799 [PubMed]
50. Cimmino A, Calin GA, Fabbri M, Iorio M V, Ferracin M, Shimizu M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. PNAS. National Academy of Sciences; 2005;102: 13944–13949. doi: 10.1073/pnas.0506654102 [PubMed]
51. Luo Q, Li X, Li J, Kong X, Zhang J, Chen L, et al. MiR-15a is underexpressed and inhibits the cell cycle by targeting CCNE1 in breast cancer. Int J Oncol. 2013;43: 1212–1218. doi: 10.3892/ijo.2013.2034 [PubMed]
52. Shinden Y, Akiyoshi S, Ueo H, Nambara S, Saito T, Komatsu H, et al. Diminished expression of MiR-15a is an independent prognostic marker for breast cancer cases. Anticancer Res. 2015;35: 123–128. [PubMed]
53. Rivas MA, Venturutti L, Huang Y-W, Schillaci R, Huang TH-M, Elizalde P V. Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development. Breast Cancer Res. 2012;14: R77 doi: 10.1186/bcr3187 [PMC free article] [PubMed]
54. Bhattacharya R, Nicoloso M, Arvizo R, Wang E, Cortez A, Rossi S, et al. MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. Cancer Res. 2009;69: 9090–9095. doi: 10.1158/0008-5472.CAN-09-2552 [PMC free article] [PubMed]
55. Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L, et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med. 2008;14: 1271–1277. doi: 10.1038/nm.1880 [PubMed]
56. Bottoni A, Piccin D, Tagliati F, Luchin A, Zatelli MC, Uberti ECD. miR-15a and miR-16-1 down-regulation in pituitary adenomas. J Cell Physiol. 2005;204: 280–285. doi: 10.1002/jcp.20282 [PubMed]
57. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435: 834–838. doi: 10.1038/nature03702 [PubMed]
58. Cappella P, Tomasoni D, Faretta M, Lupi M, Montalenti F, Viale F, et al. Cell cycle effects of gemcitabine. Int J Cancer. 2001;93: 401–408. doi: 10.1002/ijc.1351 [PubMed]
59. Huang P, Plunkett W. Induction of apoptosis by gemcitabine. Semin Oncol. 1995;22: 19–25. [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science